Table 3.
Trazodone | Placebo | P-value | |
---|---|---|---|
% Days took medication | |||
By self-report (N)* | 82.4 (63) | 83.3 (57) | .87 |
From MEMSCAP data (N) | 43.4 (51) | 37.7 (46) | .38 |
Mean ± SD number of pills per day (N)* | 1.98±0.7 (63) | 1.98±0.6 (57) | .97 |
Side effects reported, % (N)† | 3.06±3.3 (64) | 3.67±3.5 (64) | .27 |
Dry mouth | 37.5 (24) | 23.9 (16) | .13 |
Morning drowsiness | 31.3 (20) | 48.5 (32) | .05 |
Weight gain | 23.8 (15) | 28.4 (19) | .69 |
Increased thirst | 23.8 (15) | 31.3 (21) | .43 |
Daytime tiredness | 21.9 (14) | 36.9 (24) | .08 |
Nervousness | 18.8 (12) | 19.4 (13) | 1.0 |
Decreased interest in sex | 14.8 (9) | 10.6 (7) | .60 |
Headache | 14.1 (9) | 23.9 (16) | .19 |
Fast heartbeat | 12.5 (8) | 9.0 (6) | .58 |
Muscle aches | 12.5 (8) | 14.9 (10) | .80 |
Decreased appetite | 11.1 (7) | 10.5 (7) | 1.0 |
Diarrhea | 10.9 (7) | 7.5 (5) | .35 |
Dizzy on standing | 9.4 (6) | 6.0 (4) | .52 |
Runny nose | 7.8 (5) | 22.7 (15) | .03 |
Confusion | 7.8 (5) | 7.5 (5) | 1.0 |
Difficulty concentrating | 6.3 (4) | 14.9 (10) | .16 |
Uncontrolled hand movements | 6.3 (4) | 9.0 (6) | .74 |
Rash | 6.3 (4) | 3.0 (2) | .33 |
Decreased urine flow | 6.3 (4) | 3.0 (2) | .43 |
Painful/prolonged erections | 5.8 (3) | 0.0 (0) | .24 |
Nausea/vomiting | 4.7 (3) | 9.0 (6) | .49 |
Breathing trouble | 4.7 (3) | 1.5 (1) | .36 |
Blurred vision | 3.2 (2) | 10.5 (7) | .17 |
Constipation | 3.1 (2) | 9.0 (6) | .27 |
Swelling of hands/feet | 1.6 (1) | 6.0 (4) | .37 |
Mean ± SD number of side effects reported (N)†‡ | 3.06±3.3 (64) | 3.67±3.5 (64) | .27 |
% Believed they were taking trazodone (N)† | 79.0 (49) | 48.5 (32) | .0003 |
From daily sleep log data over the first 4 weeks (total N=121)
From 2-week follow-up data (total N=128)
Log-transformed variable